Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer

Clinical trial NCT06783140 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06783140
Sponsor: University Health Network, Toronto
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Pancreatic Cancer, Advanced or Metastatic BRCA1/2 Mutation PALB2 Gene Mutation

Start date: 2025-06-10
Primary completion: 2031-06-02
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.